ReviewFrontiers in pharmacology2026
Mitochondrial dysfunction and oxidative stress in autism spectrum disorder: pharmacological insights into natural antioxidants.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by social communication deficits, restricted and fixated interests and abnormal motor behaviors. Increasing evidence implicates oxidative stress, mitochondrial dysfunction, and neuroinflammation as key biological features of ASD. Aberrant redox homeostasis, reduced glutathione reserves, increased lipid peroxidation, and dysregulated NRF2 signaling have been documented in both peripheral tissues and brain samples. Post-mortem and imaging studies further reveal deficits in electron transport chain complexes and pyruvate dehydrogenase activity, suggesting a mechanistic link between mitochondrial bioenergetics and ASD-related phenotypes. These pathomechanisms have motivated interest in antioxidant metabolites from botanical drugs and nutrients as complementary strategies. To critically appraise mechanisms and levels of evidence (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.